Approval · Notice of Compliance 487 · 2003
XIGRIS: Notice of Compliance 487
Issued January 31, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 487
- Date
- January 31, 2003
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Antithrombotic profibrinolytic anti-inflammatory enzyme
Products in this notice
Medicinal ingredients
- DROTRECOGIN ALFA (ACTIVATED) 5 MG per VIAL
- DROTRECOGIN ALFA (ACTIVATED) 20 MG per VIAL